Form 4: VolitionRx CEO Butera Receives Restricted Stock Units in Lieu of Cash Compensation

Salvatore Thomas Butera, CEO of Volition Veterinary (a subsidiary of VolitionRx Ltd), received 19,300 restricted stock units (RSUs) in lieu of cash compensation on March 1, 2025.

Summary

• On March 1, 2025, Salvatore Thomas Butera, CEO of Volition Veterinary, received 19,300 restricted stock units (RSUs) under VolitionRx Ltd's 2024 Stock Incentive Plan.
• These RSUs were awarded in lieu of cash compensation.
• The RSUs vest in three installments of 6,434, 6,433, and 6,433 units on March 1, 2025, April 1, 2025, and May 1, 2025, respectively.
• The RSUs are also subject to further time-based vesting in a single installment on March 1, 2026, contingent upon continued service.
• Upon vesting and settlement, Butera will receive shares of common stock equal to the number of vested RSUs.
• Butera also reported direct ownership of 312,890 common stock shares and indirect ownership of 99,350 common stock shares jointly with his spouse.

Sentiment

Score: 7

Explanation: The document is neutral to slightly positive. It reflects a standard compensation practice, indicating confidence in the executive's continued service. There are no explicit negative indicators.

Positives

• The grant of RSUs aligns Butera's interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages continued service and commitment from the CEO.

Risks

• The value of the RSUs is dependent on the future performance of VolitionRx Ltd's stock, which is subject to market risks.
• If Butera leaves the company before the RSUs fully vest, he may forfeit a portion of the award.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, but the RSU grant suggests an expectation of continued service and contribution from the CEO.

Industry Context

Granting stock-based compensation is a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders. The specific terms of the RSU grant, such as the vesting schedule and performance conditions, are tailored to the company's specific circumstances and strategic goals.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, particularly in the biotech sector.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize stock options and RSUs as part of their executive compensation packages.
• The size and vesting schedule of the RSU grant are likely benchmarked against similar companies in the diagnostics and biotechnology space to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with theirs.
• Employees may see the grant as a sign of the company's commitment to its leadership.
• The grant has no immediate impact on customers, suppliers, or creditors.

Key Dates